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1. Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a relatively rare neurodegenerative disorder that 
causes progressive dysfunction of voluntary muscle groups secondary to motor neurons 
death. The relentless involvement of all skeletal muscles of the body, characterized by 
weakness and atrophy to complete paralysis, invariably involves respiratory muscles 
(particularly the diaphragm) resulting in a failure to deliver adequate amounts of oxygen to, 
and remove carbon dioxide from blood. As a result, respiratory failure, frequently 
complicated by pneumonia related to respiratory muscle weakness and ineffective cough, is 
the most frequent cause of death in these patients (Lo Coco et al., 2008).  
Considering the natural history of ALS, only a few number of patients shows respiratory 
muscle dysfunction at the onset of the disease (Marti-Fabregas et al., 1995; De Carvalho et 
al., 1996), and the majority of patients maintains an almost normal pulmonary function for 
months or years. Patients thus need to be regularly and progressively evaluated to identify 
early signs of respiratory muscle weakness so that adequate treatment can be implemented. 
Indeed, in the last few years it has been repeatedly shown that non-invasive positive-
pressure ventilation (NIPPV), the treatment of choice for chronic hypoventilation and 
respiratory failure in ALS, allows a significant improvement in survival and quality of life 
(Heiman-Patterson & Miller, 2006). Many tests are available to objectively assess the 
performances of the respiratory system, and there is increasing interest toward those able to 
sensitively detect mild impairment. Moreover, great attention has to be put on monitoring of 
cough effectiveness, management of respiratory secretions and prevention of respiratory 
infections. For all these reasons the management of respiratory dysfunction has become a 
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major issue in the multidisciplinary assessment of patients with ALS, and the pulmonologist 
has gained an increasing role in this process. However, there is still little consensus on 
pulmonary care worldwide, and clinical practice varies widely from country to country, 
especially when NIPPV becomes inadequate to support respiratory muscle failure. It is, 
then, good practice to discuss respiratory issues in advance with the patients and their 
carers in order to avoid emergency interventions or unwanted treatments, and frequently 
review these decisions during the course of the disease.  
This chapter focuses on the recent advances that have emerged in the management of 
pulmonary dysfunction in patients with ALS with emphasis on respiratory evaluation and 
mechanical ventilation. 
2. Evaluation of pulmonary function 
As already mentioned, when patients with ALS seek medical attention, they do not usually 
display signs of pulmonary involvement, and do not refer respiratory complaints. However, 
during the progression of the disease all patients eventually complain of dyspnea with 
exertion, orthopnea, and poor sleep quality with frequent awakenings, nightmares, early 
morning headaches or excessive daytime sleepiness (Heffernan et al., 2006; Beneditt & 
Boitano, 2008). A clinical examination at this point might show respiratory paradox, rapid 
shallow breathing or accessory muscle contraction. Nevertheless, the observation that many 
patients may remain asymptomatic even when there is a marked reduction of vital capacity 
limits the reliability of these signs and symptoms. There are, however, several dyspnea 
rating scales, such as the Borg dyspnoea score, the baseline dyspnea index and the transition 
dyspnea index, that have been recently reconsidered and their implementation has been 
encouraged (Lechtzin et al., 2007a; Just et al., 2010). 
In addition to respiratory symptoms and signs, many exams are used in the evaluation of 
pulmonary function in patients with ALS (Heffernan et al., 2006; Beneditt & Boitano, 2008; 
Lo Coco et al., 2008; Miller et al., 2009a).  
The most widely available measure for detecting respiratory decline is forced vital capacity 
(FVC) sitting and/or supine. FVC is correlated with survival, and usually presents an 
almost linear decrease during the course of the disease, but with a marked variability from 
patient to patient (within 2% to 4% of predicted value per month) (Fallat et al., 1979; Munsat 
et al., 1988; Schiffman & Belsh, 1993; Stembler et al., 1998; Czaplinski et al., 2006; Lo Coco et 
al., 2006a).  
FVC, however, has some well known limitations, such as low sensitiveness in patients with 
bulbar involvement, because of reduced buccal strength, or cognitive involvement, and a 
relative insensitiveness to detect mild or moderate diaphragmatic dysfunction. According to 
many specialists, supine FVC, although more difficult to perform, has superior sensitivity 
over seated FVC in predicting survival, is closely correlated with transdiaphragmatic 
pressure, and then should be always executed in the evaluation of patients with ALS 
(Varrato et al., 2001; Schmidt et al., 2006; Baumann et al., 2010). 
Maximal inspiratory and expiratory pressure (MIP and MEP) are other sensitive 
measurements, and it has been shown that many patients with an FVC > 70% had abnormal 
MIP (< -60 cm) (Jackson et al., 2001). However, since many patients are unable to perform 
the test with the progression of disease, in many centres these two tests are not routinely 
executed.  
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Arterial blood gas analysis may also be of help in the evaluation of patients with ALS, 
especially in those with severe bulbar involvement, since it could reveal resting hypercapnia 
(PaCO2 > 6.5 kPa) and/or hypoxemia (PaO2 < 80 mmHg). However, these are usually very 
late signs of respiratory failure in ALS.  
Sniff nasal inspiratory pressure (SNIP) is regarded as a good measure of diaphragmatic 
strength, and is probably more accurate than FVC, especially at later stages, although even 
SNIP may underestimate respiratory function in patients with bulbar involvement, because 
of upper airway collapse. However, a sniff nasal pressure test < 40% of predicted value (or < 
60 cmH2O) is a significant predictor of sleep disordered breathing, nocturnal hypoxemia, 
hypercapnia and mortality (Fitting et al., 1999; Lyall et al., 2001b; Carrat et al., 2011). 
Finally, nocturnal hypoventilation and sleep-disordered breathing are common problems in 
ALS with the progression of the disease, and can occur even when respiratory muscle function 
is only mildly affected and in the presence of normal daytime gas exchange (Gay et al., 1991; 
Ferguson et al., 1996; Arnulf et al., 2000). Nocturnal hypoventilation is particularly severe 
during rapid eye movements (REM) sleep, when all postural and accessory muscles are 
physiologically atonic, and only the diaphragm, which may itself be impaired, is left to sustain 
ventilation and overcome any upper airway resistance (Ferguson et al., 1996). Then, since 
nocturnal oximetry is easily performed and can be executed domiciliary, it has become 
frequently used in clinical practice for the evaluation of respiratory involvement in patients 
with ALS and as a guide to initiate mechanical ventilation. Nocturnal oximetry correlated with 
survival (mean SaO2 < 93 mmHg was associated with mean survival of 7 months vs 18 months 
when mean SaO2 > 93 mmHg) (Velasco et al., 2002), and nocturnal desaturations < 90% for 1 
cumulative minute was a more sensitive indicator of nocturnal hypoventilation than either 
FVC or MIP (Jackson et al., 2001). Polysomnography is not routinely performed, because is 
costly and demanding, although it can reveal causes of poor sleep quality different from 
disordered breathing, such as motor activity during sleep (Lo Coco et al., 2011). 
3. Non-invasive mechanical ventilation 
Long-term mechanical ventilation in patients with neuromuscular problems was first 
introduced between 1950 and 1960 in France and Sweden as a consequence of the 
poliomyelitis epidemics. During the following decades, the concept of home mechanical 
ventilation expanded rapidly, and long-term non-invasive positive-pressure ventilation 
(NIPPV) was implemented in many other countries and for many other conditions, 
including ALS, to treat chronic alveolar hypoventilation. 
Chronic alveolar hypoventilation is a state characterized by reduced arterial oxygen tension 
and increased carbon dioxide tension, which the patient may correct at least partially by 
voluntary hyperventilation. The underlying mechanisms are not yet fully understood and 
may involve impairment of lung mechanics or airway function and cough, ventilation-
perfusion mismatch, blunted central ventilatory drive, or respiratory muscle fatigue. 
Abnormalities may occur while awake or during sleep. In most cases, chronic alveolar 
hypoventilation leads to daytime fatigue, hypersomnia, and changes in psychological 
function. 
The application of ventilatory assistance in ALS, most frequently non-invasively, has led in 
the last fifteen years to a revolution in respiratory assistance and ventilatory support in 
these patients, with a significant impact on the natural history of the disorder. Indeed, 
NIPPV has been shown to alleviate respiratory symptoms, to extend survival considerably, 
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and to improve quality of life and cognitive functions in most patients (Miller et al., 2009a). 
At present time, NIV, usually via nasal mask with Bi-level Positive Airway Pressure (BiPAP) 
machines, is the most effective treatment available for ALS patients (Heiman-Patterson & 
Miller, 2006). 
The first study that investigated the effects of NIPPV in patients with ALS dates back to 
1995. In a non-randomized trial of NIPPV, Pinto and colleagues showed that survival was 
significantly longer in the nine patients that received NIPPV compared to the nine patients 
that received standard care (Pinto et al., 1995). In the following years, many cohort and 
retrospective studies, and a single randomized trial confirmed these results in those patients 
that used the ventilatory device for more than 4 hours/night (defined as tolerant patients) 
(Aboussouan et al., 1997, 2001; Kleopa et al., 1999; Bourke et al., 2003, 2006; Farrero et al., 
2005; Gruis et al., 2005; Lo Coco et al., 2006b). In general, these studies demonstrated a 
median survival of 10 to 15 months in those who were able to tolerate NIPPV. It was also 
pointed out that NIPPV treatment could slow the rate of respiratory impairment, while 
severe bulbar impairment could affect NIPPV tolerance (Pinto et al., 1995; Aboussouan et al., 
1997, 2001; Kleopa et al., 1999; Bourke et al., 2003, 2006; Farrero et al., 2005; Gruis et al., 2005; 
Lo Coco et al., 2006b). Furthermore, many recent studies showed that NIPPV therapy could 
improve quality of life of patients with ALS (Gelinas et al., 1998; Lyall et al., 2001a; Kaub-
Wittemer et al., 2003; Bourke et al., 2003, 2006; Mustfa et al., 2006), although some suggested 
that the caregivers’ burden could become heavier (Gelinas et al., 1998; Kaub-Wittemer et al., 
2003). Finally, it has been reported that mechanical ventilation could improve cognitive 
function after some months of treatment (Newson-Davis et al., 2001). 
Notwithstanding the aforementioned effects on respiratory symptoms, quality of life, and 
survival many studies suggest that the employment of NIPPV in ALS is poor worldwide 
(Bourke et al., 2002; Lechtzin et al., 2004), with a need for more education of clinicians and 
patients regarding the benefits of mechanical ventilation earlier in the course of the disease 
(Bradley et al., 2001). The reasons for such low uptake of NIPPV treatment are multifactorial 
but are influenced by differences in the experience of physicians, its availability and cost, 
uncertainty of the benefits and timing for starting ventilation, and concerns that ventilatory 
support might prolong suffering, render home care less feasible, and lead to dependency or 
ventilator entrapment (Radunović et al., 2007). 
Moreover, there is still debate about the optimal timing to introduce ventilation in these 
patients and whether early NIPPV initiation could actually lead to increased survival rates. 
With regard to the first aspect, as previously discussed, there are at present many different 
guidelines that suggest numerous exams to be performed, including upright and supine 
spirometry, nocturnal oximetry, blood gas analysis and MIP (Andersen et al., 2005, 2007; 
Miller et al., 2009a).  
Concerning to the effects of early NIPPV introduction in patients with ALS, there are some 
studies that reported increased compliance, quality of life and survival in those patients that 
received earlier treatment (mainly defined by the evidence of significant desaturations at 
nocturnal oximetry) (Velasco et al., 2002; Jackson et al., 2001; Pinto et al., 2003; Lechtzin et 
al., 2007b; Carratù et al., 2009), encouraging earlier use of NIPPV or the use of more sensitive 
tests to detect chronic alveolar hypoventilation. 
According to recently published guidelines, all patients with ALS could benefit from NIPPV 
therapy, and a trial with this appliance should never be discouraged, although marked 
bulbar involvement could be associated with reduced tolerance and maybe survival (Miller 
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et al., 2009a). Indeed, the increased risk of aspiration in patients with bulbar onset and 
problems because of difficulties in clearing secretions or obstructions, such as those related 
to abnormal function of the vocal cords, should be considered.  
In our experience NIPPV can be well tolerated by both patients and caregivers, even in 
patients with bulbar involvement, especially if an intensive educational training and 
adaptation on NIPPV can be performed (Volanti et al., 2011). Special importance, then, 
should be deserved to adaptation and compliance during the first few weeks of NIPPV use, 
since this could be a crucial step in determining the efficacy of the treatment. 
Factors predicting survival following NIPPV include advanced age, airway mucus 
accumulation and lower body mass index (Peysson et al., 2008; Lo Coco et al., 2006). 
Noncompliance with NIPPV has been related to frontotemporal dysfunction and severe 
bulbar involvement, whereas compliance with the treatment was associated with young age, 
preserved upper limb function, symptoms of orthopnea and dyspnea, use of percutaneous 
endoscopic gastrostomy (PEG), speech devices, and riluzole (Bourke et al., 2003, 2006; Gruis 
et al., 2005; Olney et al., 2005; Jackson et al., 2006). Nocturnal hypercapnea has also been 
recently indicated as a predictor of good compliance with subsequent NIPPV treatment 
(Kim et al., 2011). Oxygen supplementation should be avoided unless provided with 
mechanical ventilation or to treat dyspnea as a palliative, periodically monitoring CO2 
levels. In fact oxygen therapy may reduce respiratory drive particularly during sleep and 
has been associated with CO2 retention and a less favourable outcome than ventilation (Bach 
et al., 1998; Gay & Edmonds, 1995). 
At present, worldwide accepted guidelines propose NIPPV initiation in the presence of 
respiratory symptoms, and/or evidence of respiratory muscles weakness (FVC ≤ 80% of 
predicted or SNIP ≤ 40 cmH2O), evidence of significant nocturnal desaturation on overnight 
oximetry (< 90% for > 5% of the time asleep) or a morning arterial PaCO2 > 6.5 kPa 
(Radunović et al., 2007; Miller et al., 2009a). 
4. Physiotherapy and management of airway secretions 
Physiotherapy is a useful palliative adjunction in the treatment on ALS, in particular in the 
management of respiratory secretions (Lo Coco et al., 2008). Indeed, during the course of the 
disease progressive inspiratory and expiratory muscle weakness and bulbar innervated 
muscle dysfunction result in ineffective cough reflex. Coughing, an important part of the 
airway defence aiding in the removal of secretions, consists of three components: an 
inspiratory phase, a compressive phase with glottic closure, and an expulsive phase 
resulting from sudden glottic opening. Patients with ALS may develop impairment of any of 
these three phases, and as a result, clearance of respiratory secretions may become 
problematic, leading to further pulmonary complications. 
The effectiveness of mucus clearance is largely dependent on the magnitude of peak cough 
flows (PCFs) (King et al., 1985), which can be measured using a standard peak flow meter 
adapted to an anesthesia face mask. A PCF of < 2.7 L/s has been suggested to indicate an 
ineffective cough (Bach & Saporito, 1996; Tzeng & Bach, 2000). However, since PCF 
decreases during respiratory tract infections, when the pressure generated by expiratory 
muscles is reduced (Poponick et al., 1997), it has been suggested that once a patient’s PCF is 
< 4.5 L/s, particularly in the presence of bulbar dysfunction, there is a risk for pulmonary 
complications (Bach et al., 1997; Sancho et al., 2007). That threshold could be an appropriate 
time to implement assisted cough techniques. Moreover, patients with a mean PCF above 
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337 L/min had a significantly greater chance of being alive at 18 months (Chaudri et al., 
2002). 
Methods of treatment include breathing exercises, postural drainage, exercise regimens and 
the use of assisted cough techniques (Lo Coco et al., 2008). 
Medications with mucolytics like guaifenesin or N-acetylcysteine, a -receptor antagonist 
(such as metoprolol and propanolol), nebulized saline, or an anticholinergic bronchodilator 
such as ipratropium are widely used, although no controlled studies exist in ALS (Miller et 
al., 2009a).  
The benefit of breathing exercises is difficult to evaluate but their main aims can be 
summarized as: to promote a normal breathing pattern; to teach controlled breathing for use 
during attacks of dyspnoea; in conjunction with forced expiration technique and postural 
drainage to assist the removal of secretions; and to maintain the mobility of the chest wall. 
Patients must be carefully instructed by a physiotherapist and should practise these 
exercises regularly. 
Patients who have excess secretions in the bronchial tree or difficulties in secretions removal 
may benefit from postural drainage. Postural drainage can be defined as the placement of a 
patient in various positions so that, with the aid of gravity, secretions may drain from the 
peripheral to the more central areas of the lung and thus become more easily expectorated. 
The positions to be used and also the length of time spent in each position must be 
determined for each patient by a skilled physiotherapist. Clearance of bronchial secretions 
by postural drainage may be further assisted by the use of deep breathing, percussion and 
chest vibration, which may be combined with compression of the chest wall and also with 
the use of the forced expiration technique. However, patients with limited mobility and 
muscle weakness have difficulty with postural drainage and generally do not benefit from 
chest physical therapy (Kirilloff et al., 1985). Moreover, intensive cycles of physiotherapy 
may be exhausting for many patients, particularly those with advanced disease, and may 
cause arterial desaturation.  
Interestingly, a recent double-blind, randomized-controlled trial showed that inspiratory 
muscle training may potentially strengthen the inspiratory muscles and slow the decline in 
respiratory function in patients with ALS (Cheah et al., 2009). 
Among non-invasive expiratory aids, manually assisted coughing techniques, such as 
anterior chest compression and abdominal trust, have been shown to be effective in 
facilitating the elimination of airway secretions in patients with neuromuscular diseases 
(Massery & Frownfelter, 1990; Bach, 1993a). Nevertheless, manually assisted coughing is 
labour intensive and often difficult for non-professional caregivers, both during outpatient 
and in-hospital management, and it depends on precise care provider-patient coordination 
(Vianello et al., 2005). 
The mechanical in-exsufflator (MI-E) is a device that assists patients in clearing bronchial 
secretions. It consists of a two-stage axial compressor that provides positive pressure 
(that causes a deep insufflation), thereby generating a forced expiration in which high 
expiratory flow rates and a high expiratory pressure gradient are generated between the 
mouth and the alveoli. It is usually applied via a facemask. The use of MI-E has been 
described to be simple and safe enough for application by non-professional caregivers 
(Bach, 1993a, 1994), and has been proposed as a complement to manually assisted 
coughing in the prevention of pulmonary morbidity in neuromuscular patients (Tzeng & 
Bach, 2000; Bach et al., 1993b). MI-E has also been shown to be helpful in the 
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management of patients with ALS (Sancho et al., 2004) and to be effective in prolonging 
non-invasive respiratory aids delaying the need for tracheostomy (Bach, 2002). However, 
this device seems to be ineffective in patients with severe bulbar dysfunction (Bach, 2002; 
Sancho et al., 2004), perhaps because the application of the exsufflation cycle of MI-E for 
those patients with weakness of the genioglossus activity due to bulbar dysfunction 
might produce a dynamic, total, or partial collapse of the upper airway (Sancho et al., 
2004).  
It is useful to remember that for patients whose vital capacities are less than normal, 
manually assisted coughing is not optimally effective unless preceded by a maximal lung 
insufflation, and MI-E is not optimal unless an abdominal trust is applied during the 
exsufflation (Goncalves & Bach, 2005). Then abdominal trusts and MI-E should be combined 
together for effective prevention of lower respiratory tract infection and respiratory 
insufficiency. Failure to correctly administer physical medicine aids continues to make 
respiratory failure inevitable for the great majority of people with neuromuscular diseases 
(Goncalves & Bach, 2005). 
Finally, high-frequency chest-wall oscillation (HFCWO), another airway-clearance 
technique, has been recently evaluated in a 12-week randomized, controlled trial on 46 
patients with ALS (Lange et al., 2006). HFCWO is a technique that, through generation of 
high flow in the small airways, is thought to mobilize secretions from the distal airways to 
the larger airways, from where they can be more easily removed. It has been reported that 
HFCWO is well tolerated, considered to be helpful by a majority of patients, and decreases 
symptoms of breathlessness, suggesting that the intervention was useful in the clearance of 
airway secretions in patients with ALS (Lange et al., 2006). Another study, however, failed 
to show any benefit in loss of lung function or mortality in 9 patients with ALS (Chaisson et 
al., 2006). 
A part from sustaining respiration with mechanical devices, special consideration should be 
given to prevention of aspiration and development of pneumonia (Radunović et al., 2007; 
Miller et al, 2009 a,b). In this regard, it is of fundamental importance the reduction of the 
amount of salivary secretions through the use of several medications (such as amitriptyline 
and botulinum toxin injections), devoting adequate amount of time in teaching proper 
swallowing technique, and maintaining hydration. It is also useful to provide a portable 
mechanical home suction device. In addition, when dysphagia worsens, placement of a PEG 
tube should be the preferred option, especially when the respiratory function is not too 
much compromised. Smoking cessation advice should be offered to all patients who are 
current smokers. Influenza and pneumococcal immunization should be encouraged during 
the progression of the disease, although ALS has not been included in specific risk-group 
recommendations available so far. In case of acute pneumonia, adequacy and length of 
treatment, proper dosages and intervals of administration, and reduction of delay of initial 
antibiotic treatment are all important issues (American Thoracic Society, 2005; Lim et al., 
2009).  
Antibiotic prophylaxis strategies are especially useful to prevent ventilator-associated 
pneumonia, whereas passive humidifiers or heat–moisture exchangers decrease ventilator 
circuit colonization, but have not consistently reduced the incidence of ventilator-associated 
pneumonia, and thus they cannot be regarded as a pneumonia prevention tool (American 
Thoracic Society, 2005). 
www.intechopen.com
  
Amyotrophic Lateral Sclerosis 
 
586 
5. Invasive mechanical ventilation 
ALS is a relentless pathology that causes progressive muscle dysfunction. Therefore 
respiratory capacity eventually fails, despite NIPPV treatment. Indeed, at first, NIPPV is 
generally used for intermittent nocturnal support to alleviate symptoms of nocturnal 
hypoventilation, although as respiratory function worsens, patients tend to require 
increasing daytime support and eventually continuous support. When all the respiratory 
aids fail to maintain adequate blood oxygen saturation, the only intervention that allows 
survival of these patients is invasive mechanical ventilation through a tracheostomy tube. 
Treatment failure seems not to be dependent on lung or respiratory muscle function but on 
bulbar dysfunction (Bach et al., 2004).  
When placed on invasive ventilation patients are supported from a respiratory point of 
view; however, the loss of motor neurons goes on progressively, leading to complete 
paralysis and muscular atrophy. Some patients may eventually reach a “locked in” state in 
which they cannot communicate at all, because there is also total paralysis of the extraocular 
muscles. When connected to tracheostomy tubes patients may survive for many years, with 
respiratory tract infections the most frequent cause of death (Bradley et al., 2002; Hayashi & 
Oppenheimer, 2003; Lo Coco et al., 2007; Marchese et al., 2008; Vianello et al., 2011). Median 
survival time usually ranges from 2 to 4 years. Interestingly, the amyotrophic lateral 
sclerosis functional rating scale (ALSFRS), a disease-specific rating scale that assesses 
functional impairment, has been shown to predict both length of hospital stay as a result of 
acute respiratory failure and survival after initiation of invasive ventilation in these patients 
(Lo Coco et al., 2007). 
Notwithstanding its effect on survival, only a minority of patients with ALS receive invasive 
mechanical ventilation, at least in the western Countries (Moss et al., 1993; Miller et al., 2000; 
Neudert et al., 2001). On the contrary, in Japan the frequency of invasive ventilation is 
considerably higher. Many patients are treated in emergency without advance planning, 
because of a respiratory crisis, whereas the number of patients that electively choose this 
treatment is low (Moss et al., 1993, 1996; Cazzoli & Oppenheimer, 1996; Lo Coco et al., 2007). 
Socio-economic reasons may be one of the possible explanations for the low prevalence of 
invasive ventilation in ALS, given the relatively high costs of this treatment. Moreover there 
is a need for 24-hour-caregiving, which could be perceived by caregivers and relatives as 
extremely burdensome. A recent study suggested that the choice of invasive ventilation was 
consistent with a sustained sense that life was worth living in any way possible, at least for 
some time and within certain boundaries, although it may involve unrealistic expectations 
of cure by some (Rabkin et al., 2006). Moreover, the attitudes of the treating physician have 
also a great influence (Moss et al., 1993), and there is concern that tracheostomy will prolong 
life beyond the point that the patient can communicate or interact with others.  
Despite these many doubts and concerns, the majority of patients that underwent invasive 
ventilation were positive about their choice (Moss et al., 1993), reporting a satisfying quality 
of life (Cazzoli & Oppenheimer, 1996; Kaub-Wittemer et al., 2003), and indicating that they 
would repeat the choice again in the same situation. Caregivers were more frequently 
burdened and distressed by this intervention and they frequently witnessed a marked 
reduction of social life activities (Cazzoli & Oppenheimer, 1996; Gelinas et al., 1998; Kaub-
Wittemer et al., 2003; Rabkin et al., 2006). 
It is good practice that patients together with their families discuss end-of-life issues and 
preferences with the physician, so that advance directives and patient’s wishes are well 
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known in advance of a respiratory crisis (Silverstein et al., 1991; Andersen et al., 2005, 2007). 
Indeed, once intubated, patients can rarely get free from the ventilator. These preferences 
should also be reviewed periodically during the course of the disease, since patients’ desires 
concerning life-sustaining interventions might change with disease progression. Ideally, 
emergency intubation and tracheostomy should be avoided (Andersen et al., 2005, 2007), but 
this is a much debated question, since there is not universal consent from public authorities. 
As a result, the percentage of patients that had been tracheotomized without informed 
consent is very high across studies (Moss et al., 1993, 1996; Cazzoli & Oppenheimer, 1996; Lo 
Coco et al., 2007).  
Symptomatic treatment of severe dyspnea includes use of opioids (morphine) alone or in 
combination with benzodiazepines (such as lorazepam, diazepam or midazolam), if 
significant anxiety is present (Voltz & Borasio, 1997; Miller et al., 1999; Andersen et al., 2007; 
Clemens et al., 2008). Relief of dyspnea using opioids was rated as good by 81% of hospice 
patients with ALS. (O'Brien et al., 1992). Dose titration against clinical symptoms is 
recommended and rarely results in life-threatening respiratory depression. Anxiety of 
choking correlated highly significantly with the intensity of dyspnea (Clemens et al., 2008). 
Terminal relentlessness and confusion secondary to hypecapnia could be relieved by 
administration of neuroleptic drugs (Voltz & Borasio, 1997; Miller et al., 1999; Andersen et 
al., 2007). 
There are some case series offering practical advice for withdrawing both invasive and non-
invasive ventilation, including frequent and repeated discussions and counseling with the 
patient and his family, assessment for discomfort, such as dyspnea, agitation, or anxiety, 
and symptom management during the withdrawal process with morphine and 
benzodiazepines (such as diazepam) (Borasio &, Voltz, 1998; Ankrom et al., 2001; O'Mahony 
et al., 2003). However, there are no controlled studies specifically examining withdrawal of 
ventilation in ALS (Miller et al., 2009b).  
6. Conclusion 
Recent publications provided important contributions to many aspects of respiratory care 
for patients with ALS, such as non-invasive ventilation and assisted cough. There is a need 
for regular assessment and follow up of respiratory function, and investigations should 
include daytime assessment of respiratory function (including FVC and SNIP) as well as 
sleep studies in order to ensure early recognition of patients with respiratory muscle 
impairment (Lo Coco et al., 2008). 
At present time the only approved pharmacological treatment for ALS is riluzole, which 
extends survival by about 2 months (Miller et al., 2007). On the other hand, NIPPV 
treatment allows survival for longer periods of time, improves quality of life, and may 
probably alter the disease course. As a consequence, NIPPV should be considered a major 
treatment option in patients with chronic hypoventilation or in whom respiratory 
impairment has become evident during sleep despite normal diurnal respiratory function. 
Every effort, then, should be made to improve NIPPV implementation in the management 
of patients with ALS worldwide, since it is still underutilized. The degree of hypoventilation 
that should prompt introduction of NIPPV must be defined further, even if there is a general 
tendency toward earlier intervention. Nocturnal hypoventilation could be particularly 
useful for this purpose. 
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Prevention of aspiration and pneumonia, and adequate management of bronchial secretions 
are two other important issues. Adequate treatment of sialorrhea and dysphagia are 
important in the reduction of pneumonia risk. Insufficient cough is a condition that can be 
diagnosed by measuring peak cough flow and should, whenever present, be treated in 
patients with ALS. There is some evidence that the MI-E device could be of help in cough 
assistance, except for patients with severe bulbar dysfunction, but further research is 
needed, as well as randomized trials that compare the MI-E with other techniques of 
assisted coughing. 
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years, Amyotrophic Lateral Sclerosis (ALS) remains one of the mysterious diseases of the 21st century. Great
efforts have been made to develop pathophysiological models and to clarify the underlying pathology, and with
novel instruments in genetics and transgenic techniques, the aim for finding a durable cure comes into scope.
On the other hand, most pharmacological trials failed to show a benefit for ALS patients. In this book, the
reader will find a compilation of state-of-the-art reviews about the etiology, epidemiology, and pathophysiology
of ALS, the molecular basis of disease progression and clinical manifestations, the genetics familial ALS, as
well as novel diagnostic criteria in the field of electrophysiology. An overview over all relevant pharmacological
trials in ALS patients is also included, while the book concludes with a discussion on current advances and
future trends in ALS research.
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